Powered by Google

2018-35: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration

Medical retina
Drug research
Investigator Initiated Research
Inclusion open since 26-2-2019

The purpose of this clinical study is to evaluate the efficacy and safety of 0.5 mg and 1.0 mg conbercept intravitreal injection compared with the vascular endothelial

growth factor antagonist active control, aflibercept intravitreal injection (2.0 mg, Eylea®, Regeneron Pharmaceuticals, Inc.), in subjects with neovascular age-related macular degeneration.

By visiting eyehospital.nl you are accepting the use of cookies. Read more about cookies.

Hide this message